Switzerland Archives

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when would CRISPR Therapeutics file for an IPO? News arrived today that the company had finally applied to the US […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

Could Artificial Enzymes be the Future of Synthetic Chemistry?

As synthetic organic chemistry struggles to reinvent itself, the field is shifting its focus to emulating and engineering enzymes. A team of researchers in Basel has developed an artificial metalloenzyme with unique functionality that can be activated in a cell. Since the first example was published in 2015, artificial enzymes have been a hot topic […]

September 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Sep 2016

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Tecentriq could be Roche’s ticket to the top of immuno-oncology. The checkpoint inhibitor just reached its co-primary endpoints in Phase III trials for non-small cell lung cancer and could bring the company €4.5B. Roche’s Tecentriq (atezolizumab) has demonstrated that it is a force to be reckoned with by clearing Phase III clinical trials for non-small cell […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 31 Aug 2016

Novartis’ second FDA Biosimilar Approval could unlock Billions

Novartis just attained FDA approval for a second biosimilar in the US. Erelzi will unlock the €4.5B rheumatoid arthritis market cornered by Enbrel. Sandoz, a division of Novartis based in the Munich area, has taken home another trophy from the biosimilar battleground by scoring a second FDA approval for its copycat, Erelzi (etanercept-szzs). This drug mimics Enbrel, a €4.5B franchise managed by Amgen in the US that treats rheumatoid arthritis as well […]

August 31, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

ADHD is believed to affect up to 7% of people worldwide, but some common therapies bear a shocking resemblance to Speed. A new drug from NLS, Mazindol, just entered Phase II and could set a new non-amphetaminic standard. The treatment of Attention Deficit Hyperactive Disorder (ADHD) is hotly debated in the US, were almost 10% […]

August 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Aug 2016

Antibodyomes for faster Discovery of Biologicals, with Memo Therapeutics

After delighting ourselves with fabulous French gastronomy in Nancy, it’s time to say our farewells and head to the next border. Basel is our final destination. Our goal? Get to know a bit more of Swiss-based company Memo Therapeutics, our Biotech of the Week. City: Basel, Switzerland Founded: 2010 Employees: 10 Financial Data: €2.1M Total Raised (as of […]

August 26, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 4 Aug 2016

Roche drops Partnership for Hepatitis Immunotherapy

While everybody wants to get the next immunotherapy on the market, Roche is turning its back on one. It’s leaving the partnership with Inovio, which focuses on developing a DNA-based immunotherapy to treat Hepatitis B. Previously, Roche has left projects to focus on immunotherapies, particularly in the hype field of immuno-oncology. This was an important […]

August 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

nootkatone evolva natural mosquito repellant zika

News and Trends 27 Jul 2016

SynBio Nootkatone now in trials to stop the Spread of Zika

The grapefruit aroma nootkatone is now in field trials to assess its effectiveness against mosquitoes that spread the Zika virus. Good news for Evolva, which figured out a SynBio process to produce the compound. Recently, the Zika went from being considered a mild virus to a public health emergency. As the virus was linked with infant microcephaly, there […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

cell medimmune influenza a antibody biotech

News and Trends 21 Jul 2016

‘Winner Antibody’ holds promise as universal Influenza A Vaccine

MedImmune and Humabs have reasons to be happy. Their candidate for an Influenza A vaccine has made it into well-known journal, Cell, boasting a unique affinity to the virus with multiple mechanisms to stop infection. The promising candidate is MEDI8852, an antibody initially developed by Humabs (Switzerland). It targets Influenza A virus (the group of viruses known as avian flu), […]

July 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 18 Jul 2016

Switzerland discovers Pomegranate ‘Anti-Ageing’ Effect and founds Biotech

Researchers at the École Polytechnique Fédérale de Lausanne (EPFL) have uncovered a molecule in the pomegranate fruit which can prolong the lifespan of animal models. The co-authors who published in Nature went to co-found a biotech Amazentis to develop the wonder molecule into clinical trials. There are many underlying factors to what happens to our bodies as we age. However, […]

July 18, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 15 Jul 2016

UK Biotech buys Swiss Antibodies to accelerate CAR-T Development

Cell Medica is a London-based biotech which develops, manufactures and markets personalised cell immunotherapeutics for infectious disease and cancer. It has therefore just acquired a Swiss antibody manufacturing biotech Delenex, to help its progress into the CAR-T field. Update 20/07/16: Cell Medica has also just received EMA Orphan Drug Designation for their CMD-003 candidate. This means it can obtain regulatory and […]

July 15, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Jul 2016

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

Getting up from a wheelchair is a shared dream of paralyzed people all across the world. A dream that might soon become true thanks to a new skin-like implant that directly stimulates the patients’ spinal cord through electric pulses. The sci-fi technology developed by researchers at École Polytechnique Fédérale of Lausanne (EPFL) in Switzerland has […]

July 14, 2016 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

CRISPR Therapeutics applies to go Public in another Massive IPO

Could Artificial Enzymes be the Future of Synthetic Chemistry?

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Novartis’ second FDA Biosimilar Approval could unlock Billions

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

Antibodyomes for faster Discovery of Biologicals, with Memo Therapeutics

Roche drops Partnership for Hepatitis Immunotherapy

SynBio Nootkatone now in trials to stop the Spread of Zika

‘Winner Antibody’ holds promise as universal Influenza A Vaccine

Switzerland discovers Pomegranate ‘Anti-Ageing’ Effect and founds Biotech

UK Biotech buys Swiss Antibodies to accelerate CAR-T Development

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!